UB-421 not checked
UBP Greater China (Shanghai) Co., Ltd · United BioPharma · dB4C7 mAb
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.”In the company’s words, NCT04985890 on ClinicalTrials.gov
- Tested for
- HIV-1-infection
- Main trialPhase 2
- “* To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption. * To evaluate the safety and tolerability of UB-421 combined with chidamide among HIV-1 suppressed patients who undergo short-term ART interruption.”In the company’s words, NCT04985890 on ClinicalTrials.gov
- Other names
- dB4C7 mAb
Other drugs for HIV-1-infection
- ACC017Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 3
- AlimatravirMerck & Co. · Phase 3
- IslatravirMerck & Co. · Phase 2/3
- UlonivirineMerck & Co. · Phase 2/3
- ISL/ULOMerck & Co. · Phase 2/3
- CabotegravirViiV Healthcare · Phase 3
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Dec 2026 | A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir | |
| Phase 3Withdrawn | 31 Dec 2025 | To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults | |
| Phase 3Unknown | 30 Jun 2026 | UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | |
| Phase 2Completed | 15 Oct 2020 | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | |
| Phase 2Completed | 1 Feb 2023 | A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs | |
| Phase 2Unknown | Mar 2024 | UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients | |
| Phase 2Unknown | 30 Jun 2024 | The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients | |
| Phase 1Completed | 25 May 2022 | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients | |
| Phase 1Unknown | 31 Dec 2025 | Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026